• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

65.32 -0.16 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 967,139
Open 65.50
Bid (Size) 64.70 (200)
Ask (Size) 65.09 (400)
Prev. Close 65.48
Today's Range 63.79 - 65.77
52wk Range 29.31 - 70.98
Shares Outstanding 95,640,600
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗
April 23, 2026
Via Chartmill
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
March 23, 2026
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+5.8%
+5.8%
1 Month
+2.9%
+2.9%
3 Month
+3.4%
+3.4%
6 Month
+8.5%
+8.5%
1 Year
+61.6%
+61.6%

More News

Read More
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗
February 24, 2026
Via Chartmill
CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗
February 14, 2026
Via Chartmill
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
March 21, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
March 21, 2026
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
March 20, 2026
Via The Motley Fool
News headline image
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗
March 09, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗
February 24, 2026
Via The Motley Fool
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
February 23, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
February 19, 2026
Via MarketMinute
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
January 22, 2026
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
January 08, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
January 16, 2026
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
January 07, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026
January 02, 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
January 02, 2026
From Grabar Law Office
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
December 30, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Alexandria Real Estate Equities, Inc. (NYSE: ARE); Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your
December 29, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
December 22, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗
December 19, 2025
Via Stocktwits
News headline image
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? ↗
December 19, 2025
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Cytokinetics, Incorporated - Common Stock publicly traded?
Yes, Cytokinetics, Incorporated - Common Stock is publicly traded.
What exchange does Cytokinetics, Incorporated - Common Stock trade on?
Cytokinetics, Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cytokinetics, Incorporated - Common Stock?
The ticker symbol for Cytokinetics, Incorporated - Common Stock is CYTK on the Nasdaq Stock Market
What is the current price of Cytokinetics, Incorporated - Common Stock?
The current price of Cytokinetics, Incorporated - Common Stock is 65.32
When was Cytokinetics, Incorporated - Common Stock last traded?
The last trade of Cytokinetics, Incorporated - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of Cytokinetics, Incorporated - Common Stock?
The market capitalization of Cytokinetics, Incorporated - Common Stock is 6.25B
How many shares of Cytokinetics, Incorporated - Common Stock are outstanding?
Cytokinetics, Incorporated - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap